BRIEF-Charles River Laboratories International Inc - Dsa Net Book-To-Bill Improved Each Month Since Q3 2025 - SEC Filing

Reuters12-03

Dec 3 (Reuters) - Charles River Laboratories International Inc CRL.N:

CHARLES RIVER LABORATORIES INTERNATIONAL INC - DSA NET BOOK-TO-BILL IMPROVED EACH MONTH SINCE Q3 2025 - SEC FILING
CHARLES RIVER LABORATORIES INTERNATIONAL- SEASONALITY DURING HOLIDAY PERIODS IN Q4 AND IN EARLY JAN MAY IMPACT NEAR-TERM PROPOSAL, BOOKING ACTIVITY

Source text: [ID:n0001628280-25-054902]

Further company coverage: CRL.N

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2588460010?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-03 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588460010","market":"us","top_or_hot":-1,"title":"BRIEF-Charles River Laboratories International Inc - Dsa Net Book-To-Bill Improved Each Month Since Q3 2025 - SEC Filing","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Charles River Laboratories International Inc - Dsa Net Book-To-Bill Improved Each Month Since Q3 2025 - SEC Filing</title></head><body><p><span>Dec 3 (Reuters)</span><span> - </span>Charles River Laboratories International Inc <span>CRL.N</span>:</p><ul><li><p>CHARLES RIVER LABORATORIES INTERNATIONAL INC - DSA NET BOOK-TO-BILL IMPROVED EACH MONTH SINCE Q3 2025 - SEC FILING</p></li><li><p>CHARLES RIVER LABORATORIES INTERNATIONAL-  SEASONALITY DURING HOLIDAY PERIODS IN Q4 AND IN EARLY JAN MAY IMPACT NEAR-TERM PROPOSAL, BOOKING ACTIVITY</p></li></ul><p>Source text: [ID:n0001628280-25-054902]</p><p>Further company coverage: <span>CRL.N</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Charles River Laboratories International Inc - Dsa Net Book-To-Bill Improved Each Month Since Q3 2025 - SEC Filing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Charles River Laboratories International Inc - Dsa Net Book-To-Bill Improved Each Month Since Q3 2025 - SEC Filing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-03 21:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Charles River Laboratories International Inc - Dsa Net Book-To-Bill Improved Each Month Since Q3 2025 - SEC Filing</title></head><body><p><span>Dec 3 (Reuters)</span><span> - </span>Charles River Laboratories International Inc <span>CRL.N</span>:</p><ul><li><p>CHARLES RIVER LABORATORIES INTERNATIONAL INC - DSA NET BOOK-TO-BILL IMPROVED EACH MONTH SINCE Q3 2025 - SEC FILING</p></li><li><p>CHARLES RIVER LABORATORIES INTERNATIONAL-  SEASONALITY DURING HOLIDAY PERIODS IN Q4 AND IN EARLY JAN MAY IMPACT NEAR-TERM PROPOSAL, BOOKING ACTIVITY</p></li></ul><p>Source text: [ID:n0001628280-25-054902]</p><p>Further company coverage: <span>CRL.N</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nFWN3X80ZW:1","article_id":"2588460010","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588460010","pubTimestamp":1764766930,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Charles River Laboratories International Inc - Dsa Net Book-To-Bill Improved Each Month Since Q3 2025 - SEC FilingDec 3  - Charles River Laboratories International Inc CRL.N:CHARLES RIVER LABORATORIES INTERNATIONAL INC - DSA NET BOOK-TO-BILL IMPROVED EACH MONTH SINCE Q3 2025 - SEC FILINGCHARLES RIVER LABORATORIES INTERNATIONAL-  SEASONALITY DURING HOLIDAY PERIODS IN Q4 AND IN EARLY JAN MAY IMPACT NEAR-TERM PROPOSAL, BOOKING ACTIVITYSource text: [ID:n0001628280-25-054902]Further company coverage: CRL.N ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","LU0757428866.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC","IE00BFMHRM44.USD":"NEUBERGER BERMAN GLOBAL EQUITY MEGATRENDS \"A\" (USD) ACC","BK4530":"医药外包概念","BK4121":"生命科学工具和服务","LU1815336091.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","CRL":"查尔斯河","BK4588":"碎股"},"translate_title":"简介-Charles River Laboratories International Inc-自2025年第三季度以来，Dsa净预订账单逐月改善-SEC备案","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRL":0.9},"content_text":"BRIEF-Charles River Laboratories International Inc - Dsa Net Book-To-Bill Improved Each Month Since Q3 2025 - SEC FilingDec 3 (Reuters) - Charles River Laboratories International Inc CRL.N:CHARLES RIVER LABORATORIES INTERNATIONAL INC - DSA NET BOOK-TO-BILL IMPROVED EACH MONTH SINCE Q3 2025 - SEC FILINGCHARLES RIVER LABORATORIES INTERNATIONAL-  SEASONALITY DURING HOLIDAY PERIODS IN Q4 AND IN EARLY JAN MAY IMPACT NEAR-TERM PROPOSAL, BOOKING ACTIVITYSource text: [ID:n0001628280-25-054902]Further company coverage: CRL.N ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2588460010","isCrawlerRequest":true}